INVO Fertility

INVO Fertility ROCE

The Return on Capital Employed (ROCE) of INVO Fertility (IVF) as of Oct 28, 2026 is -80.84 %. In the previous year, Return on Capital Employed (ROCE) was -63.25 % — a change of 27.82% (lower).

ROCE

-80.84 %

YoY

27.82%

Last updated:

In 2025, INVO Fertility's return on capital employed (ROCE) was -80.84 %, a 27.82% increase from the -63.25 % ROCE in the previous year.

The INVO Fertility ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
96.69 USD
Jan 1, 2019
48.15 USD
Jan 1, 2020
-96.03 USD
Jan 1, 2021
-73.66 USD
Jan 1, 2022
1,107.82 USD
Jan 1, 2023
-793.29 USD
Jan 1, 2024
-63.25 USD
Jan 1, 2025
-80.84 USD
The INVO Fertility ROCE history
YEARROCEYoY
-80.84 %+27.82%
-63.25 %-92.03%
-793.29 %-171.61%
1,107.82 %-1,604.03%
-73.66 %-23.30%
-96.03 %-299.43%
48.15 %-50.20%
96.69 %+653.71%
12.83 %-71.93%
45.70 %+188.55%
15.84 %-58.92%
38.55 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

INVO Fertility Stock analysis

What does INVO Fertility do? INVO Bioscience Inc generates revenue through its flagship product INVOcell, a medical device enabling intravaginal culture (IVC) for fertility treatment. The company commercializes its IVC technique by operating three INVO Centers in North America, offering patients an affordable alternative to in vitro fertilization (IVF). INVO Centers provide a more connected and intimate experience by incubating oocytes and sperm within the woman’s body, targeting individuals seeking accessible fertility care globally. The company also acquires existing IVF clinics to expand its market reach and integrate IVC into established fertility services. INVOcell and IVC are positioned as cost-effective solutions compared to traditional IVF, appealing to patients prioritizing affordability and a natural process. The commercial strategy focuses on opening new INVO Centers and acquiring IVF clinics, creating a dual revenue stream from device sales and procedure fees at affiliated centers. This approach targets the global assisted reproductive technology (ART) market, emphasizing inclusivity and accessibility for diverse patient segments. The company’s revenue model relies on direct patient treatment at INVO Centers and partnerships with acquired IVF clinics, where IVC procedures are integrated. By making fertility care more affordable and intimate, INVO Bioscience Inc addresses unmet needs in the ART sector, particularly for patients who find IVF too expensive or impersonal. The business model is built around scaling its IVC technique through strategic center openings and clinic acquisitions to capture a growing segment of the fertility market. INVO Fertility is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling INVO Fertility's Return on Capital Employed (ROCE)

INVO Fertility's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing INVO Fertility's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

INVO Fertility's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in INVO Fertility’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about INVO Fertility stock

Return on Capital Employed (ROCE) of INVO Fertility is -80.84 % in 2025.

Return on Capital Employed (ROCE) of INVO Fertility changed from -63.25 % to -80.84 %, representing a 27.82% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) INVO Fertility since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s INVO Fertility with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — INVO Fertility

All Key Metrics — INVO Fertility